CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Trilaciclib hydrochloride
CAS:<p>Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).</p>Fórmula:C24H32Cl2N8OPureza:99.69% - 99.89%Forma y color:SolidPeso molecular:519.47Avotaciclib
CAS:<p>Avotaciclib (BEY1107) is a potent and orally active cyclin dependent kinase 1 (CDK1) inhibitor.Avotaciclib can be used to study locally advanced or metastatic</p>Fórmula:C13H11N7OPureza:98.02%Forma y color:SolidPeso molecular:281.27Cyclin K degrader 1
<p>Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.</p>Fórmula:C23H17Cl2N5O2Pureza:99.76%Forma y color:SolidPeso molecular:466.32Cirtuvivint
CAS:<p>Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.</p>Fórmula:C24H25N7OPureza:99.46% - >99.99%Forma y color:SolidPeso molecular:427.5NU6140
CAS:<p>NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).</p>Fórmula:C23H30N6O2Pureza:98.33%Forma y color:SolidPeso molecular:422.52XPW1
CAS:<p>XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.</p>Fórmula:C36H39ClFN7O2Pureza:98.08%Forma y color:SoildPeso molecular:656.19Lerociclib dihydrochloride
CAS:<p>Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/</p>Fórmula:C26H36Cl2N8OPureza:97.4%Forma y color:SolidPeso molecular:547.52MBQ-167
CAS:<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Fórmula:C22H18N4Pureza:98.07% - 99.52%Forma y color:SolidPeso molecular:338.41Garcinone C
CAS:<p>Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.</p>Fórmula:C23H26O7Pureza:99.13% - 99.92%Forma y color:SolidPeso molecular:414.45CDK2-IN-4
CAS:<p>CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.</p>Fórmula:C23H18N6O2SPureza:97.24% - 99.10%Forma y color:SolidPeso molecular:442.49Ca2+ channel agonist 1
CAS:<p>Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.</p>Fórmula:C19H26N6OPureza:97.71%Forma y color:SolidPeso molecular:354.45Simurosertib
CAS:<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Fórmula:C17H19N5OSPureza:99.93% - 99.93%Forma y color:SolidPeso molecular:341.43(R)-CR8
CAS:<p>(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.</p>Fórmula:C24H29N7OPureza:98.41%Forma y color:SolidPeso molecular:431.53Amantadine hydrochloride
CAS:<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Fórmula:C10H18ClNPureza:99.98%Forma y color:Solid CrystallinePeso molecular:187.71Nimbolide
CAS:<p>Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.</p>Fórmula:C27H30O7Pureza:95.84% - 99.4%Forma y color:SolidPeso molecular:466.52NVP-2
CAS:<p>NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).</p>Fórmula:C27H37ClN6O2Pureza:99.13%Forma y color:SolidPeso molecular:513.07hSMG-1 inhibitor 11j
CAS:<p>hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.</p>Fórmula:C27H28ClN7O3SPureza:99.22% - 99.65%Forma y color:SolidPeso molecular:566.07(±)-Enitociclib
CAS:<p>(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.</p>Fórmula:C19H18F2N4O2SPureza:99.29%Forma y color:SolidPeso molecular:404.43Ribociclib succinate
CAS:<p>Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Fórmula:C27H36N8O5Pureza:99.9%Forma y color:SolidPeso molecular:552.63Samuraciclib hydrochloride
CAS:<p>Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).</p>Fórmula:C22H31ClN6OPureza:98.99% - 99.8%Forma y color:SolidPeso molecular:430.97CDK4/6-IN-2
CAS:<p>CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。</p>Fórmula:C27H32F2N8Pureza:99.47%Forma y color:SolidPeso molecular:506.59CDKI-73
CAS:<p>CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.</p>Fórmula:C15H15FN6O2S2Pureza:98.11%Forma y color:SolidPeso molecular:394.45BRD6989
CAS:<p>BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.</p>Fórmula:C16H16N4Pureza:99.43%Forma y color:SolidPeso molecular:264.33MeBIO
CAS:<p>MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.</p>Fórmula:C17H12BrN3O2Pureza:99.64%Forma y color:SolidPeso molecular:370.2(E/Z)-THZ1 2HCl
CAS:<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Fórmula:C31H30Cl3N7O2Pureza:99.51%Forma y color:SolidPeso molecular:638.98CPS2
CAS:<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Fórmula:C38H42N12O10S2Forma y color:SolidPeso molecular:890.94CDK9/EZH2-IN-1
CAS:<p>CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.</p>Fórmula:C47H59N11O4S2Forma y color:SolidPeso molecular:906.17CDK9 degrader-1
<p>CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.</p>Fórmula:C32H34Cl2N6O4Forma y color:SolidPeso molecular:637.56(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Forma y color:SolidPeso molecular:513.38BSJ-5-63
CAS:<p>BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.</p>Fórmula:C52H74ClN9O6S2Forma y color:SolidPeso molecular:1020.78CDK2/4-IN-1
<p>CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.</p>Forma y color:Odour SoliddCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Fórmula:C14H11ClN4OSPureza:98.48% - 99.41%Forma y color:SolidPeso molecular:318.78WAY-322243
CAS:<p>WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.</p>Fórmula:C18H18N2O2SPureza:99.88%Forma y color:SoildPeso molecular:326.41JWZ-5-13
<p>JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.</p>Fórmula:C54H66N10O6SPeso molecular:982.48875CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Fórmula:C24H22FN7O2Forma y color:SolidPeso molecular:459.48JH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161[Ala92]-p16 (84-103)
CAS:<p>Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.</p>Fórmula:C93H155N31O26Pureza:98%Forma y color:SolidPeso molecular:2123.44Anticancer agent 264
<p>Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.</p>Fórmula:C23H18ClF5N6OForma y color:SolidPeso molecular:524.87Eciruciclib
CAS:<p>Eciruciclib is an inhibitor of CDK with antitumor properties.</p>Fórmula:C27H33FN8Pureza:99.73%Forma y color:SolidPeso molecular:488.6CDK2-IN-7
CAS:<p>CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).</p>Fórmula:C24H30N6O4SForma y color:SolidPeso molecular:498.6NecroIr1
<p>NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.</p>Fórmula:C40H29ClIrN5OForma y color:SolidPeso molecular:823.36A-130A
CAS:<p>A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.</p>Fórmula:C47H78O13Pureza:98%Forma y color:SolidPeso molecular:851.11NecroIr2
<p>NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.</p>Fórmula:C46H30ClIrN6O2Forma y color:SolidPeso molecular:926.44CDK7/9-IN-1
CAS:<p>CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.</p>Fórmula:C24H32F3N5O2Forma y color:SolidPeso molecular:479.548Roccellic Acid
CAS:<p>Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.</p>Fórmula:C17H32O4Forma y color:SolidPeso molecular:300.43CDK7-IN-21
CAS:<p>CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .</p>Fórmula:C33H36FN9O2Forma y color:SolidPeso molecular:609.7Cimpuciclib
CAS:<p>Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.</p>Fórmula:C30H35FN8OForma y color:SolidPeso molecular:542.663CDK9 ligand 3
CAS:<p>CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.</p>Fórmula:C18H18BrCl2N5O3Forma y color:SolidPeso molecular:503.177CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Forma y color:Odour SolidBLINK15
<p>BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.</p>Forma y color:Odour SolidCDK7-IN-2 hydrochloride hydrate
CAS:<p>CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.</p>Fórmula:C26H42ClN7O4Forma y color:SolidPeso molecular:552.123-Methylthienyl-carbonyl-JNJ-7706621
CAS:<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Fórmula:C14H14N6O3S2Forma y color:SolidPeso molecular:378.43LSN3106729 hydrochloride
CAS:<p>LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.</p>Fórmula:C25H29ClF2N8OForma y color:SoildPeso molecular:531.00Olomoucine
CAS:<p>Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.</p>Fórmula:C15H18N6OPureza:99.77%Forma y color:White Crystalline PowderPeso molecular:298.34PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Fórmula:C43H51FN12O7Forma y color:SolidPeso molecular:866.94PROTAC CDK9 degrader-7
CAS:<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Fórmula:C43H50Cl2N8O9Forma y color:SoildPeso molecular:893.81BSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Fórmula:C43H48N10O8Forma y color:SolidPeso molecular:832.9CGP-74514
CAS:<p>CGP-74514,CDK1 inhibitor (IC50=25 nM). Induces G2/M arrest, apoptosis. Used in bladder cancer research.</p>Fórmula:C19H24ClN7Pureza:98.54%Forma y color:SoildPeso molecular:385.89PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Fórmula:C43H56N10O5Forma y color:SolidPeso molecular:792.97JH-XVI-178
CAS:<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Fórmula:C22H22ClN7OForma y color:SolidPeso molecular:435.92FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidCDK7-IN-6
CAS:<p>CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.</p>Fórmula:C26H34ClN9OForma y color:SolidPeso molecular:524.07PROTAC CDK9 degrader-5
CAS:<p>PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.</p>Fórmula:C42H48Cl2N8O9Pureza:98%Forma y color:SolidPeso molecular:879.78AM5992
CAS:<p>AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.</p>Fórmula:C27H33FN8OPureza:98%Forma y color:SoildPeso molecular:504.6HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Fórmula:C28H29Cl2F3N4O4Forma y color:SolidPeso molecular:613.46CDK-IN-12
CAS:<p>CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].</p>Fórmula:C26H29FN6OSForma y color:SolidPeso molecular:492.61CDK12-IN-4
CAS:<p>CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).</p>Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.432SNX7
CAS:<p>SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.</p>Fórmula:C15H14N2OPureza:99.05%Forma y color:SolidPeso molecular:238.28CDK6/9-IN-1
CAS:<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Fórmula:C22H25ClN8OForma y color:SolidPeso molecular:452.95LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Fórmula:C37H43N5OForma y color:SolidPeso molecular:573.77CDK4/6-IN-11
CAS:<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Fórmula:C43H49N11O7Forma y color:SolidPeso molecular:831.92PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Fórmula:C40H42N12O5Peso molecular:770.34011Men 10376
CAS:<p>Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.</p>Fórmula:C57H68N12O10Pureza:98%Forma y color:SolidPeso molecular:1081.22CDK7-IN-5
CAS:<p>CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).</p>Fórmula:C34H45N9O2Forma y color:SolidPeso molecular:611.795PROTAC CDK9 degrader-2
CAS:<p>PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.</p>Fórmula:C39H36N6O10Pureza:98%Forma y color:SolidPeso molecular:748.74XY028-133
CAS:<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Fórmula:C53H67N11O7SPureza:97.11%Forma y color:SolidPeso molecular:1002.23Cdk2/Cyclin Inhibitory Peptide II
CAS:<p>Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].</p>Fórmula:C110H200N48O25Forma y color:SolidPeso molecular:2595.07EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Fórmula:C24H16N6OS2Pureza:98%Forma y color:SolidPeso molecular:468.55BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Forma y color:LiquidCDK4/6-IN-5
CAS:<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Fórmula:C22H28ClFN6O4SForma y color:SolidPeso molecular:527.01Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Forma y color:Odour SolidCDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Fórmula:C20H21F2N9Forma y color:SolidPeso molecular:425.448TMX-2138
CAS:<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Fórmula:C40H43BrFN9O11SForma y color:SolidPeso molecular:956.791CDK9 inhibitor HH1
CAS:<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Fórmula:C13H15N3OSPureza:99.92%Forma y color:SolidPeso molecular:261.34Abemaciclib metabolite M18
CAS:<p>Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.</p>Fórmula:C25H28F2N8OPureza:98%Forma y color:SolidPeso molecular:494.54PROTAC CDK9 degrader-8
<p>PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].</p>Fórmula:C44H52Cl2N10O7Pureza:98%Forma y color:SolidPeso molecular:903.85CDK9-IN-25
<p>CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.</p>Fórmula:C15H16FN5Pureza:98%Forma y color:SolidPeso molecular:285.32EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Forma y color:SolidPeso molecular:884.99Cdk2/Cyclin Inhibitory Peptide I
<p>CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.</p>Fórmula:C111H196N48O23Pureza:98%Forma y color:SolidPeso molecular:2571.05CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Fórmula:C20H20BrF3N6O2Forma y color:SolidPeso molecular:513.319[pThr3]-CDK5 Substrate
CAS:<p>[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].</p>Fórmula:C53H100N15O15PPureza:98%Forma y color:SolidPeso molecular:1218.43PROTAC CDK9 degrader-11
CAS:<p>PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)</p>Fórmula:C39H48Cl2N10O5Forma y color:SolidPeso molecular:807.768IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Fórmula:C23H32FN5O2SiForma y color:SolidPeso molecular:457.625EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Fórmula:C30H20N6OSPureza:98%Forma y color:SolidPeso molecular:512.58CDK5-IN-1
CAS:<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Fórmula:C24H25FN6O3SForma y color:SolidPeso molecular:496.56YKL-5-124 TFA
CAS:<p>YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.</p>Fórmula:C30H34F3N7O5Forma y color:SolidPeso molecular:629.63Cell Cycle Compound Library
<p>A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Forma y color:Odour SolidCDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Fórmula:C19H27N7OForma y color:SolidPeso molecular:369.464CDK1-IN-2
CAS:<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Fórmula:C17H11ClN2OPureza:98.53%Forma y color:SoildPeso molecular:294.73
![[Ala92]-p16 (84-103)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP2133.webp&w=3840&q=75)
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
